MedTrace Logo

Role of Montelukast in Asthma and Allergic Rhinitis Patients

NCT03380975 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2020-01-03

No results posted yet for this study

Summary

To determine the effect of Montelukast in Asthma and Allergic rhinits patients

Conditions

  • Asthma and Allergic Rhinitis

Interventions

DRUG

Montelukast 10mg

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening

Sponsors & Collaborators

  • Clinision

    lead OTHER

Principal Investigators

  • Faisal Faiyaz, FCPS,FCPS · Dow University of Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-28
Primary Completion
2019-03-25
Completion
2019-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03380975 on ClinicalTrials.gov